Asset Details
Do you wish to reserve the book?
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study
Do you wish to request the book?
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study
2007
Overview
The alpha-emitter radium-223 (
223Ra) is a bone-seeking radionuclide studied as a new treatment for patients with bone metastases from hormone-refractory prostate cancer. We aimed to study mature outcomes from a randomised, multicentre, phase II study of
223Ra.
Patients with hormone-refractory prostate cancer and bone pain needing external-beam radiotherapy were assigned to four intravenous injections of
223Ra (50 kBq/kg, 33 patients) or placebo (31 patients), given every 4 weeks. Primary endpoints were change in bone-alkaline phosphatase (ALP) concentration and time to skeletal-related events (SREs). Secondary endpoints included toxic effects, time to prostate-specific-antigen (PSA) progression, and overall survival. All tests were done at a 5% significance level, based on intention to treat.
Median relative change in bone-ALP during treatment was −65·6% (95% CI −69·5 to −57·7) and 9·3% (3·8–60·9) in the
223Ra group and placebo groups, respectively (p<0·0001, Wilcoxon ranked-sums test). Hazard ratio for time to first SRE, adjusted for baseline covariates, was 1·75 (0·96–3·19, p=0·065, Cox regression). Haematological toxic effects did not differ significantly between two groups. No patient discontinued
223Ra because of treatment toxicity. Median time to PSA progression was 26 weeks (16–39) versus 8 weeks (4–12; p=0·048) for
223Ra versus placebo, respectively. Median overall survival was 65·3 weeks (48·7–∞) for
223Ra and 46·4 weeks (32·1–77·4) for placebo (p=0·066, log rank). The hazard ratio for overall survival, adjusted for baseline covariates was 2·12 (1·13–3·98, p=0·020, Cox regression).
223Ra was well tolerated with minimum myelotoxicity, and had a significant effect on bone-ALP concentrations. Larger clinical trials are warranted to study
223Ra on the prevention of SREs and on overall survival in patients with hormone-refractory prostate cancer. Bone-targeting properties of
223Ra could also potentially be used for treating skeletal metastasis from other primary cancers.
Publisher
Elsevier Ltd,Elsevier Limited
Subject
/ Adenocarcinoma - radiotherapy
/ Adenocarcinoma/radiotherapy/secondary
/ Aged
/ Alkaline Phosphatase - blood
/ Bone Neoplasms - radiotherapy
/ Bone Neoplasms/radiotherapy/secondary
/ Hematology, Oncology and Palliative Medicine
/ Humans
/ Male
/ Neoplasm
/ Placebos
/ Prostatic Neoplasms - pathology
/ Prostatic Neoplasms - radiotherapy
